Berry Wealth Group LP Takes $251,000 Position in DexCom, Inc. $DXCM

Berry Wealth Group LP purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,873 shares of the medical device company’s stock, valued at approximately $251,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Andra AP fonden acquired a new stake in DexCom during the second quarter valued at approximately $26,000. Zions Bancorporation National Association UT bought a new stake in shares of DexCom in the 1st quarter valued at approximately $27,000. Anderson Financial Strategies LLC acquired a new stake in shares of DexCom during the 1st quarter valued at approximately $37,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth $45,000. Finally, Atlantic Union Bankshares Corp acquired a new position in DexCom in the second quarter worth $70,000. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Canaccord Genuity Group set a $99.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, October 31st. Royal Bank Of Canada dropped their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. TD Cowen decreased their target price on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. Finally, UBS Group cut their price target on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.73.

Insiders Place Their Bets

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the transaction, the director directly owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of DexCom stock in a transaction on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the sale, the director directly owned 37,994 shares of the company’s stock, valued at $2,096,128.98. This trade represents a 9.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 9,999 shares of company stock worth $619,391. Corporate insiders own 0.32% of the company’s stock.

DexCom Trading Up 1.5%

Shares of DXCM stock opened at $63.46 on Friday. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The firm has a market capitalization of $24.75 billion, a PE ratio of 44.07, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40. The stock has a fifty day moving average of $64.31 and a two-hundred day moving average of $75.89. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 21.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.